INKT — MiNK Therapeutics, Inc.

Is INKT overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of November 17, 2026

MiNK Therapeutics, Inc. (INKT) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $9.35. The rating moved from Strong Oversold to Oversold on November 12, 2026.

See all oversold Healthcare stocks →

AI analysis

MiNK Therapeutics is a small‑cap biotech whose outlook is heavily dependent on clinical and partnership catalysts and constrained by limited public financial disclosure. Absent clear near‑term positive clinical readouts or strategic transactions, the stock is likely to track small‑cap biotech volatility and liquidity dynamics, while sector flows favoring large, defensive pharma could mute upside. Key near‑term drivers to monitor are cash runway, any filing/clinical announcements, and signs of meaningful business development interest.

Key factors

  • Limited public financial and filing information available (no recent EDGAR comparisons provided), increasing uncertainty about fundamentals and cash runway
  • Small‑cap biotech profile: future value is likely driven primarily by clinical development milestones or partnership/licensing activity
  • Macro/sector backdrop in the last session showed risk-on leaning toward rate‑sensitive large caps and defensives, which can reduce appetite for early‑stage biotech risk
  • Potential near‑term catalysts include clinical readouts, IND/CTA milestones, or business development announcements that could move the stock materially
  • Typical small‑cap liquidity constraints and higher intraday volatility versus larger healthcare names
  • Capital markets dependence — need for follow‑on financing could lead to dilution absent clear revenue or partnering paths

Risks

  • Clinical trial failures or delays that eliminate expected value drivers
  • Short cash runway leading to dilutive financing or unfavorable partnership terms
  • Regulatory setbacks or prolonged review timelines
  • Competition from larger, better‑funded biopharma companies or platform technologies
  • Low trading liquidity producing outsized price moves on limited news
  • Shifts in investor preference toward large‑cap defensive pharma and away from small biotech risk
  • General market volatility and policy uncertainty that reduce risk appetite for speculative names

See today's live rating, score and targets

Members see the live hourly rating for INKT — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.